A 12-week Parallel Group, Randomized, Placebo-controlled, Double-blinded, Multi-center Study to Evaluate Efficacy and Safety of 2 Concentrations of SAF312 Eye Drops (5 mg/ml and 15 mg/ml) Used Twice-daily in the Treatment of Post-operative Corneal Induced Chronic Pain (CICP) Following Photorefractive Keratectomy (PRK) or Laser-assisted in Situ Keratomileusis (LASIK) Surgeries
Latest Information Update: 24 Apr 2024
Price :
$35 *
At a glance
- Drugs Libvatrep (Primary)
- Indications Ocular pain; Postoperative pain
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 29 Sep 2023 According to Bausch & Lomb media release, study results anticipated to be completed in the second half of 2023.
- 29 Jun 2023 Status changed from active, no longer recruiting to completed.
- 06 Feb 2023 Status changed from recruiting to active, no longer recruiting.